Entinostat

Entinostat

Names
IUPAC names Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl] methyl]carbamate
Other names SNDX-275; MS-275
Identifiers
CAS Number	209783-80-2 Y
3D model (Jmol)	Interactive image
ChEBI	CHEBI:132082 N
ChEMBL	ChEMBL27759 N
ChemSpider	4111 N
ECHA InfoCard	100.158.999
IUPHAR/BPS	7007
KEGG	D09338 Y
PubChem	4261
UNII	1ZNY4FKK9H Y
InChI InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) N Key: INVTYAOGFAGBOE-UHFFFAOYSA-N N InChI=1/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) Key: INVTYAOGFAGBOE-UHFFFAOYAU
SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
Properties
Chemical formula	C21H20N4O3
Molar mass	376.4085 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.^[1]

Entinostat inhibits class I HDAC1 and HDAC3 with IC₅₀ of 0.51 μM and 1.7 μM, respectively.^[2]

Syndax pharmaceuticals currently holds the rights to Entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.^[3]

Clinical trials

There is an ongoing phase II trial studying the effect of entinostat on Hodgkin's lymphoma.^[4] It is in other phase II trials for advanced breast cancer (in combination with aromatase inhibitors)^[5] and for metastatic lung cancer (in combination with erlotinib).^[6] As of September 2013, the Food and Drug Administration is working with the industry to design phase III clinical trials. They seek to evaluate the application of Entinostat for the reduction, or prevention of, treatment resistance to aromatase inhibitors in hormone receptor positive breast cancer.^[7]

References